PharmaDepth

Asset

Apalutamide

Johnson & Johnson Common Stock

Revenue

PeriodRevenue
Q2 2026$995.0M
Q1 2026$949.0M
Q3 2025$936.0M
Q2 2025$908.0M
Q1 2025$771.0M
Q3 2024$790.0M
Q2 2024$736.0M
Q1 2024$689.0M
Q3 2023$631.0M
Q2 2023$567.0M
Q1 2023$542.0M
Q3 2022$490.0M
Q2 2022$450.0M
Q1 2022$400.0M
Q3 2021$344.0M
Q2 2021$302.0M
Q1 2021$261.0M
Q3 2020$206.0M
Q2 2020$170.0M
Q1 2020$143.0M
Q3 2019$86.0M
Q2 2019$69.0M
Q1 2019$61.0M

Revenue as reported by this company. A combination product's amount appears on each of its constituent assets, so those figures are not additive.

Clinical trials (17)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT02162836phase1completed2014-06-272019-05-27Janssen Pharmaceutical K.K.A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT02924766phase1completed2016-10-032019-07-18Janssen Research & Development, LLCA Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)
NCT04557059phase3active_not_recruiting2020-11-122029-08-27Janssen Pharmaceutica N.V., BelgiumA Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
NCT03523442phase1active_not_recruiting2018-08-312019-07-09Janssen Research & Development, LLCA Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
NCT04523207phase2completed2020-08-192023-10-23Janssen Research & Development, LLCA Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

FDA applications (1)

ApplicationTypeApplicant
NDA 210951NDAJANSSEN BIOTECH INC

Marketed products (2)

  • ERLEADA
  • ERLEADA